LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

Home・Akcijų sąrašas・CytomX Therapeutics Inc

CytomX Therapeutics Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

2.98 1.71

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

2.81

Max

3.01

Pagrindiniai rodikliai
By Trading Economics
Pajamos	8.3M -18M
Pardavimai	9.6M 10M
P/E Sektoriaus vid.	22.5 49.888
Pelnas, tenkantis vienai akcijai	-0.1
Pelno marža	-177.89
Darbuotojai	69
EBITDA	8M -19M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+318.37% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-08-06

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-270M 640M
Ankstesnė atidarymo kaina	1.27
Ankstesnė uždarymo kaina	2.98

Naujienos nuotaikos

By Acuity

11%

89%

11 / 344 reitingas Healthcare

CytomX Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-06-09 23:49; UTC

Rinkos pokalbiai

Nikkei May Fall Following Tech Stock Declines on Wall Street -- Market Talk

2026-06-09 23:45; UTC

Įsigijimai, susijungimai, perėmimai

Correct: Sigma Healthcare: Has Engaged in Preliminary Discussions in Boots Sale Process

2026-06-09 23:44; UTC

Įsigijimai, susijungimai, perėmimai

Sigma Healthcare Says No Certainty That Any Transaction Will Eventuate

2026-06-09 23:44; UTC

Įsigijimai, susijungimai, perėmimai

Sigma Healthcare: Continuously Reviews Opportunities to Create Value For Shareholders

2026-06-09 23:43; UTC

Įsigijimai, susijungimai, perėmimai

Sigma Healthcare: Has Engaged in Preliminary Discussions to Sell Boots

2026-06-09 23:35; UTC

Rinkos pokalbiai

Oil Rises on Escalating Supply Disruption Concerns -- Market Talk

2026-06-09 22:06; UTC

Įsigijimai, susijungimai, perėmimai

Samsung: Element Has Expanded Rapidly Since 2022 Launch of AVITI

2026-06-09 22:05; UTC

Įsigijimai, susijungimai, perėmimai

Samsung: Element to Speed Commercialization of Gene-Sequencing Products

2026-06-09 22:05; UTC

Įsigijimai, susijungimai, perėmimai

Samsung: Additional Investment Makes It Largest Shareholder in Element

2026-06-09 22:05; UTC

Įsigijimai, susijungimai, perėmimai

Samsung Electronics Raises Stake in Element Biosciences With $175 Million Investment

2026-06-09 20:51; UTC

Uždarbis

Micron, Marvell, Super Micro, Coherent, Smucker, and More Stocks That Explain Today's Market -- Barrons.com

2026-06-09 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-06-09 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-06-09 20:09; UTC

Rinkos pokalbiai

Cryptocurrency Traders Look for Bitcoin Bottom -- Market Talk

2026-06-09 19:36; UTC

Rinkos pokalbiai

Cattle Climbs as Crude Oil Falls -- Market Talk

2026-06-09 19:32; UTC

Rinkos pokalbiai

Barclays Oil Price Outlook Contingent on Hormuz Reopening -- Market Talk

2026-06-09 19:25; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Slip in Rangebound Trade -- Market Talk

2026-06-09 19:00; UTC

Rinkos pokalbiai

Oil Settles Lower on Continued Hopes for Middle East Deal -- Market Talk

2026-06-09 18:52; UTC

Įsigijimai, susijungimai, perėmimai

Warner Bros. Stock Hits a Low. Its Paramount Merger Return Is Getting Buzz. -- Barrons.com

2026-06-09 18:47; UTC

Rinkos pokalbiai

No World Cup Inflation Seen So Far in Mexico -- Market Talk

2026-06-09 18:37; UTC

Rinkos pokalbiai

Canada's Cooling Trade With the U.S. -- Market Talk

2026-06-09 18:27; UTC

Rinkos pokalbiai

Precious Metals Lower as Trump Vows Military Response -- Market Talk

2026-06-09 17:35; UTC

Rinkos pokalbiai

Treasury Yields, Dollar Briefly Rise on Trump's Iran Retaliation Threat -- Market Talk

2026-06-09 17:30; UTC

Rinkos pokalbiai

Trump Post on Apache Helicopter Causes Brief Spike in Oil -- Market Talk

2026-06-09 16:34; UTC

Rinkos pokalbiai

Cryptocurrency Weakness Follows Selling in Equities -- Market Talk

2026-06-09 16:20; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-06-09 16:20; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-06-09 16:20; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Health Care Roundup: Market Talk

2026-06-09 15:28; UTC

Rinkos pokalbiai

Gold Futures Fall Further as Rate Fears Prevail -- Market Talk

2026-06-09 15:25; UTC

Rinkos pokalbiai

Oil Extends Losses, Falling More Than 3.5% -- Market Talk

Akcijų palyginimas

Kainos pokytis

CytomX Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

318.37% į viršų

12 mėnesių prognozė

Vidutinis 12.3 USD 318.37%

Aukščiausias 16 USD

Žemiausias 6 USD

Remiantis 10 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines CytomX Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

10 ratings

Pirkti

Laikyti

Parduoti

Remiantis 10 analitikų, pateikusių CytomX Therapeutics Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Rinkos nuotaikos

By Acuity

11 / 344 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę CytomX Therapeutics Inc

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.